VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
BSX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
BSXBoston Scientific Corporation
$43.03$64.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
BSX logo

Boston Scientific Corporation

BSX
NYSE · Medical Devices
$43.03
At close - Nov 17, 4:00 PM EST - USD
Market Cap$63.96B
P/E17.9x
52W High$102.71
Volume12.64M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Acquisition-Fueled Growth Faces Decelerating Organic Momentum Test

Boston Scientific's revenue growth has decelerated sharply from roughly 22% in mid-2025 to 1.4% in the latest quarter, suggesting that headline results may depend materially on acquisitions rather than an organic engine.

GrowthMixed
ProfitabilityModerate
ValuationAttractive
TechnicalsWeak
Explore valuation models
MARKET ACTION

BSX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

12/12 Beats

EPS beat 12 of last 12 quarters

02

Valuation risk

-51% Peers

P/E is 51% below peer median

03

Market leadership

RS 27 · Lag

Laggard (Underperforming 73% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Jan 28
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue growth slowed from roughly 22% to 1.4% over recent quarters while gross margin of 66.7% remains above peers, though operating margin fluctuated between 12.9% and 22.8%, suggesting inconsistent operating leverage.

Analyst Consensus+27.0% target
Buy(44 analysts)
34 Buy10 Hold0 Sell

The Bull Case

Upside Catalysts

Minimally invasive leadership

Boston Scientific Corporation is recognized for its leadership in minimally invasive medical devices, driving innovation in the healthcare sector.

Strong institutional ownership

Vanguard Group holds a significant 9.8% stake in Boston Scientific Corporation, indicating strong institutional confidence in the company.

Attractive valuation metrics

With trailing and forward P/E ratios of 50.06 and 26.95 respectively, Boston Scientific Corporation presents compelling valuation opportunities for investors.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
BSX-54.57%
S&P 500 (^GSPC)+7.21%
1-Year Return
BSX-57.71%
S&P 500 (^GSPC)+10.03%
3-Year Return
BSX-20.81%
S&P 500 (^GSPC)+61.31%
5-Year Return
BSX+3.41%
S&P 500 (^GSPC)+53.62%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
17.9x
Forward P/EExpansion
13.6x
EV/EBITDA0th %ile
13.5x
FCF YieldCash Flow
5.2%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
17.9x
61.8x
0th· Low
EV/EBITDA
13.5x
27.6x
0th· Low
Price/FCF
19.2x
49.7x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$38.61-10.3%
Base (Fair)$67.16+51.5%
Bull$119.69+178.2%
$38.61 Bear$67.16 Base$119.69 Bull
Current Market Price: $43.03
Trades at a 35.9% discount to Base DCF ($67.16)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$20.07B+19.9% YoY
Net income FY25
$2.89B+55.7% YoY
Free cash flow FY25
$3.66B+38.3% YoY
Operating margin FY25
19.8%+4.0 pts YoY
ROIC (FY25)8.8%
Avg ROIC 5Y6.6%
ROE (TTM)13.7%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate12/12 (100%)
Revenue Beat Rate12/12 (100%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 28, 2026
$0.73+0.4%
vs $0.73
$5.1B+1.0%
vs $5.1B
Q3 2026
Jul 29, 2026
$0.86+3.0%
vs $0.83
$5.4B+1.2%
vs $5.4B
Q2 2026
Apr 22, 2026
$0.80+1.5%
vs $0.79
$5.2B+0.6%
vs $5.2B
Q1 2026
Feb 4, 2026
$0.80+2.4%
vs $0.78
$5.3B+0.1%
vs $5.3B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·22h ago
Boston Scientific Corporation $BSX Position Reduced by AlTi Global Inc.

AlTi Global Inc. decreased its position in Boston Scientific Corporation (NYSE: BSX) by 76.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,109 shares of the medical equipment provider's stock after selling 16,135 shares during the quarter. AlTi Global Inc.'s holdings in

Zacks Investment Research·1d ago
Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?

Boston Scientific BSX saw modest sales growth in the third quarter, with revenues climbing 1.5% year over year to $5.14 billion, though its adjusted earnings per share (“EPS”) dipped 2.7% to 73 cents year over year. Primarily due to unexpected headwinds within two high-growth franchises, WATCHMAN and Electrophysiology (“EP”), the company lowered its expectations for the rest of the year.

Defense World·2d ago
108,682 Boston Scientific Corporation $BSX Shares Bought by Aberdeen Group plc

Aberdeen Group plc increased its position in shares of Boston Scientific Corporation (NYSE: BSX) by 3.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,175,308 shares of the medical equipment provider's stock after acquiring an additional 108,682 shares during the period.

Defense World·4d ago
Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027

Boston Scientific (NYSE: BSX) executives said they expect durable growth across the company's interventional portfolio, while acknowledging that its pulsed field ablation and WATCHMAN businesses face competitive challenges through 2027. Lance Bates, executive vice president and president of interventional cardiology and vascular therapies, said the company's breadth of products and planned launches support an aspiration for

Filtered for Boston Scientific CorporationMore Headlines
04

Compare before deciding

Benchmark BSX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Boston Scientific Corporation (BSX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
BSX logoBSXBoston Scientific CorporationCurrent
$43.03$63.96B17.9019.87%16.56%13.74%—
MDT logoMDTMedtronic plc
$102.32$131.37B25.148.43%13.93%10.51%2.76%
EW logoEWEdwards Lifesciences Corporation
$105.43$60.71B59.6311.55%15.3%9.65%—
SYK logoSYKStryker Corporation
$317.54$121.73B33.7211.16%13.78%15.61%1.06%
ZBH logoZBHZimmer Biomet Holdings, Inc.
$102.09$19.75B25.467.2%8.96%6.05%0.94%
BDX logoBDXBecton, Dickinson and Company
$215.42$59.36B51.61-10.91%5.66%3.67%1.93%

Compare BSX vs Peers

Boston Scientific Corporation (BSX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MDT

Most directly comparable listed peer for BSX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare BSX against a more recognizable public peer.

Peer Set

Compare Top 5

vs MDT, EW, SYK, ZBH

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

BSX SEC Filings & Documents

Boston Scientific Corporation (BSX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 28, 2026·SEC

Material company update

Oct 7, 2026·SEC

Material company update

Aug 26, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 17, 2026·SEC

FY 2025

Feb 18, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 2, 2026·SEC

FY 2026

Aug 3, 2026·SEC

FY 2025

Nov 3, 2025·SEC

Get notified when BSX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

BSX Frequently Asked Questions

Boston Scientific Corporation (BSX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Boston Scientific Corporation's revenue?

Boston Scientific Corporation (BSX) reported $21.07B in revenue over the trailing twelve months. Revenue was $20.07B in fiscal year 2025. That is 1273% more than the $1.46B of fiscal year 1996.

How fast is Boston Scientific Corporation growing?

Boston Scientific Corporation (BSX) grew revenue by 8.9% over the trailing twelve months, compared with the twelve months before.

Is BSX profitable?

Yes. Boston Scientific Corporation (BSX) earned $3.49B in net income over the trailing twelve months (a 16.6% net margin).

Dividend & Returns
What is BSX's return on equity?

Boston Scientific Corporation (BSX) had a return on equity (ROE) of 13.7% over the trailing twelve months. That is in line with the market's typical 10-15%.

What is Boston Scientific Corporation's free cash flow?

Boston Scientific Corporation (BSX) generated $3.33B in free cash flow over the trailing twelve months.

What if you invested $1,000 in BSX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →